A new computational drug repurposing method using established disease-drug pair knowledge
暂无分享,去创建一个
Sorin Draghici | Michele Donato | Nafiseh Saberian | Azam Peyvandi-Pour | Sahar Ansari | S. Drăghici | S. Ansari | M. Donato | Azam Peyvandi-Pour | Nafiseh Saberian | Michele Donato
[1] Zuping Zhang,et al. Network-Based Inference Methods for Drug Repositioning , 2015, Comput. Math. Methods Medicine.
[2] Alex E. Lash,et al. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..
[3] Elisabeth Petit-Teixeira,et al. Transcriptome Analysis Describing New Immunity and Defense Genes in Peripheral Blood Mononuclear Cells of Rheumatoid Arthritis Patients , 2009, PloS one.
[4] Jeffrey A Whitsett,et al. EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis. , 2008, American journal of physiology. Lung cellular and molecular physiology.
[5] Nasser Ghadiri,et al. A review of network‐based approaches to drug repositioning , 2018, Briefings Bioinform..
[6] S. Sehgal,et al. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.:II. FERMENTATION, ISOLATION AND CHARACTERIZATION , 1975 .
[7] Chuang Liu,et al. Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference , 2012, PLoS Comput. Biol..
[8] E. Grace,et al. Trimipramine in rheumatoid arthritis: a randomized double-blind trial in relieving pain and joint tenderness. , 1986, Current medical research and opinion.
[9] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[10] Werner E. Siebert,et al. Lasers in the Musculoskeletal System , 2001, Springer Berlin Heidelberg.
[11] M. Delorenzi,et al. Identification of Prognostic Molecular Features in the Reactive Stroma of Human Breast and Prostate Cancer , 2011, PloS one.
[12] Ivana V. Yang,et al. The Peripheral Blood Transcriptome Identifies the Presence and Extent of Disease in Idiopathic Pulmonary Fibrosis , 2012, PloS one.
[13] H. Ghofrani,et al. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond , 2006, Nature Reviews Drug Discovery.
[14] Barry D Kahan,et al. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study , 2000, The Lancet.
[15] David S. Wishart,et al. DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..
[16] Lin Lu,et al. Machine Learning and Network Methods for Biology and Medicine , 2015, Comput. Math. Methods Medicine.
[17] Gereon Hüttmann,et al. Experimental Photodynamic Laser Therapy for Rheumatoid Arthritis Using Photosan-3, 5-ALA-Induced PPIX and BPD Verteporfin in an Animal Model , 2001 .
[18] S T Roweis,et al. Nonlinear dimensionality reduction by locally linear embedding. , 2000, Science.
[19] Sorin Drăghici,et al. Statistics and Data Analysis for Microarrays Using R and Bioconductor , 2016 .
[20] Joel Dudley,et al. Exploiting drug-disease relationships for computational drug repositioning , 2011, Briefings Bioinform..
[21] L. Xu,et al. Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial–mesenchymal transition and fibroblast activation , 2013, Cell Death and Disease.
[22] T. Ashburn,et al. Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.
[23] Emre Guney,et al. A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection , 2018, npj Systems Biology and Applications.
[24] Yan Zhao,et al. Drug repositioning: a machine-learning approach through data integration , 2013, Journal of Cheminformatics.
[25] Joel Dudley,et al. Network-Based Elucidation of Human Disease Similarities Reveals Common Functional Modules Enriched for Pluripotent Drug Targets , 2010, PLoS Comput. Biol..
[26] H. Lehrach,et al. Molecular signatures and new candidates to target the pathogenesis of rheumatoid arthritis. , 2010, Physiological genomics.
[27] Salvatore Alaimo,et al. Drug–target interaction prediction through domain-tuned network-based inference , 2013, Bioinform..
[28] F. Iorio,et al. Transcriptional data: a new gateway to drug repositioning? , 2013, Drug discovery today.
[29] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[30] Salvatore Alaimo,et al. Recommendation Techniques for Drug-Target Interaction Prediction and Drug Repositioning. , 2016, Methods in molecular biology.
[31] S. Schreiber,et al. Chemistry and biology of the immunophilins and their immunosuppressive ligands. , 1991, Science.
[32] Natalia Novac,et al. Challenges and opportunities of drug repositioning. , 2013, Trends in pharmacological sciences.
[33] S. Sehgal,et al. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. , 1975, The Journal of antibiotics.
[34] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[35] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[36] Xiuzhen Han,et al. The antitumor activity of the fungicide ciclopirox , 2010, International journal of cancer.
[37] R. Tagliaferri,et al. Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.
[38] Jaana Kekäläinen,et al. Cumulated gain-based evaluation of IR techniques , 2002, TOIS.
[39] Alexander A. Morgan,et al. Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.
[40] Van V. Brantner,et al. Estimating the cost of new drug development: is it really 802 million dollars? , 2006, Health affairs.
[41] Zora Modrusan,et al. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis , 2014, Thorax.
[42] P. Mahalanobis. On the generalized distance in statistics , 1936 .
[43] J. Holden,et al. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. , 1997, Human pathology.
[44] Peng Sun,et al. Drug repurposing by integrated literature mining and drug-gene-disease triangulation. , 2017, Drug discovery today.
[45] Z. Szallasi,et al. Sequence-matched probes produce increased cross-platform consistency and more reproducible biological results in microarray-based gene expression measurements. , 2004, Nucleic acids research.
[46] M. Dickson,et al. The cost of new drug discovery and development. , 2004, Discovery medicine.
[47] E. Tobinick. The value of drug repositioning in the current pharmaceutical market. , 2009, Drug news & perspectives.
[48] F. Klamt,et al. Alzheimer’s disease master regulators analysis: search for potential molecular targets and drug repositioning candidates , 2018, Alzheimer's Research & Therapy.
[49] Erika Melissari,et al. Effect of prolonged phenytoin administration on rat brain gene expression assessed by DNA microarrays , 2010, Experimental biology and medicine.
[50] Takeshi Fukuda,et al. Gefitinib prevents bleomycin-induced lung fibrosis in mice. , 2006, American journal of respiratory and critical care medicine.
[51] Georg Schett,et al. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. , 2010, Arthritis and rheumatism.
[52] Alan F. Scott,et al. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2004, Nucleic Acids Res..
[53] B. Munos. Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.
[54] I. Jolliffe. Principal Component Analysis , 2002 .
[55] Francesmary Modugno,et al. A Potential Role for the Estrogen-metabolizing Cytochrome P450 Enzymes in Human Breast Carcinogenesis , 2003, Breast Cancer Research and Treatment.
[56] Rafael A Irizarry,et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.
[57] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[58] A. Barabasi,et al. Network-based in silico drug efficacy screening , 2016, Nature Communications.
[59] T. Libermann,et al. Testing New Drugs for Treatment of Melanoma Patients Applying Connectivity Map Database Analysis with Melanoma Gene Signatures , 2012 .
[60] Robert D Davis,et al. Bayesian probit regression model for the diagnosis of pulmonary fibrosis: proof-of-principle , 2011, BMC Medical Genomics.
[61] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.